TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A Being Patient report explains four leading theories for what causes Alzheimer’s disease: amyloid buildup, tau damage, inflammation and vascular or other contributing processes. These theories explain parts of the disease, but researchers have not established one complete cause; current evidence supports interacting mechanisms and leaves important questions open.
Alzheimer’s disease has no single established cause, and researchers are investigating several biological processes that may contribute to the progressive loss of brain cells. A Being Patient report outlines four leading theories—amyloid, tau, inflammation and vascular or other interacting factors—while emphasizing that each explains only part of the disease.
The theories focus on processes that can damage neurons and the connections through which they communicate. Alzheimer’s commonly affects the hippocampus early, contributing to difficulty forming new memories; as damage spreads, language, judgment, behavior and coordination can also be affected. The source cites the Alzheimer’s Association’s 2026 report as estimating 7.4 million Americans aged 65 and older are living with Alzheimer’s dementia.
The amyloid hypothesis proposes that beta-amyloid fragments accumulate outside neurons, forming plaques and potentially setting off other damage, including tau changes. The tau theory focuses on abnormal tau proteins inside neurons. Tau normally helps maintain the cell’s internal transport system; when it malfunctions and forms tangles, that system can break down. The report presents inflammation and vascular or other contributing processes as additional lines of research, not as settled explanations or mutually exclusive alternatives.
Evidence for amyloid’s role has influenced treatment and diagnosis, but it does not establish that plaques alone cause the disease. FDA-approved antibodies Leqembi (lecanemab) and Kisunla (donanemab) modestly slowed cognitive decline in clinical trials among people in early Alzheimer’s stages, according to the source; they are not cures and carry risks, including brain swelling and bleeding, requiring monitoring. The report also says the FDA cleared a blood test to aid in identifying amyloid pathology in May 2025.
How Theories Shape Treatment
Understanding what drives Alzheimer’s matters because different causal explanations point to different ways to detect or treat the disease. The amyloid theory has guided much drug development and made amyloid measurements relevant to diagnosis. Yet the mixed history of anti-amyloid drugs cautions against treating one biological marker as a complete explanation for memory loss and other symptoms.
The reported trial results for lecanemab and donanemab suggest that targeting amyloid can produce a modest slowing of decline for some people at early stages. That is different from reversing Alzheimer’s or preventing it. Their risks and the need for monitoring also matter to patients and clinicians weighing treatment. Research into tau, inflammation and vascular factors may help explain why people with similar amyloid findings can have different disease courses and could inform other approaches.
As an affiliate, we earn on qualifying purchases.
From Plaques to Multiple Mechanisms
In 1906, German psychiatrist Alois Alzheimer described abnormalities in the brain of a former patient, Auguste Deter: clumps between brain cells and twisted fibers within them. These findings later became known as amyloid plaques and tau tangles, hallmarks that remain central to research. Their presence, however, did not settle what initiates the disease or how the abnormalities relate to symptoms.
For decades, amyloid has been the dominant research explanation. Beta-amyloid is produced from a larger protein associated with neuron membranes and is normally cleared from the brain. Researchers propose that its buildup can begin years before symptoms and may contribute to a chain of later changes. Amyloid can be measured using PET scans or spinal-fluid testing; the source also notes the FDA’s May 2025 clearance of a blood test to aid in identifying related pathology.
The treatment record has been mixed. The FDA-approved drug Aduhelm (aducanumab) reduced plaques, but its clinical benefit was unconvincing, and its maker discontinued it in 2024, the report says. Newer antibodies have shown modest effects in trials, while raising safety and monitoring concerns. Together, these developments make the distinction between changing a disease marker and meaningfully changing a person’s condition especially relevant.
““Both γ-secretase and β-secretase inhibitors, which strongly inhibit amyloid-beta production, worsen cognitive and clinical performance in early and late stages of Alzheimer’s disease.””
— Bruno Imbimbo, researcher at Chiesi Farmaceutici, quoted by Being Patient
As an affiliate, we earn on qualifying purchases.
What Still Drives Cell Damage
The initiating cause remains unknown. The report describes several leading theories but does not establish which process starts Alzheimer’s, whether one process is primary, or how the proposed mechanisms interact in different people. Amyloid plaques and tau tangles are established disease hallmarks; their exact roles in triggering and spreading neuron damage remain under investigation.
It is also unclear why treatments that affect amyloid produce limited clinical benefit in trials, or which patients are most likely to benefit. The source reports modest slowing in early-stage trials, not a cure or evidence that every person with Alzheimer’s will respond. The precise contribution of inflammation, vascular health and other factors—and how those factors relate to amyloid and tau—also remains unresolved.
As an affiliate, we earn on qualifying purchases.
Evidence From Ongoing Research
Researchers will continue testing treatments that target amyloid, tau and other suspected contributors, while studying how these processes relate to symptoms and disease progression. Further clinical trial results and longer-term monitoring will help clarify the size and durability of treatment effects, as well as risks. Diagnostic research, including blood tests that aid in identifying amyloid pathology, will also need to be interpreted alongside clinical assessment.
For readers, the immediate takeaway is that these are research theories, not competing diagnoses or a settled account of why an individual develops Alzheimer’s. The evidence may change as studies report results; decisions about testing or treatment should be discussed with a qualified health professional.
As an affiliate, we earn on qualifying purchases.
Key Questions
What are the four leading theories about Alzheimer’s causes?
The report discusses amyloid buildup, tau damage, inflammation, and vascular or other contributing processes. They may interact, and none alone is established as a complete explanation.
Do amyloid plaques prove what causes Alzheimer’s?
No. Plaques are a recognized Alzheimer’s hallmark and can be detected by several tests, but researchers are still determining whether and how amyloid initiates or contributes to neuron damage.
Do current Alzheimer’s drugs cure the disease?
No. The report says lecanemab and donanemab modestly slowed cognitive decline in trials among people in early stages. They are not cures and have risks that require medical monitoring.
What remains unknown about Alzheimer’s?
Researchers have not established what starts the disease, how amyloid, tau, inflammation and vascular factors interact, or why disease progression and treatment response differ among people.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
